175 related articles for article (PubMed ID: 34423228)
1.
Kelly AD; Wiklund T; Kononen J; Creeden J
JCO Precis Oncol; 2021 Aug; 5():. PubMed ID: 34423228
[No Abstract] [Full Text] [Related]
2. Primary resistance to alectinib in a patient with STRN-ALK-positive non-small cell lung cancer: A case report.
Sun K; Nie L; Nong L; Cheng Y
Thorac Cancer; 2021 Jun; 12(12):1927-1930. PubMed ID: 33960639
[TBL] [Abstract][Full Text] [Related]
3.
Gerthofer V; Scheiter A; Lüke F; Keil F; Utpatel K; Pöhmerer LM; Seitz J; Niessen C; Ignatov A; Dietmaier W; Calvisi DF; Evert M; Ortmann O; Seitz S
JCO Precis Oncol; 2021; 5():. PubMed ID: 34568722
[No Abstract] [Full Text] [Related]
4. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
5. Case Report of Non-Small Cell Lung Cancer with STRN-ALK Translocation: A Nonresponder to Alectinib.
Nakanishi Y; Masuda S; Iida Y; Takahashi N; Hashimoto S
J Thorac Oncol; 2017 Dec; 12(12):e202-e204. PubMed ID: 29169525
[No Abstract] [Full Text] [Related]
6. Mixed responses to first-line alectinib in non-small cell lung cancer patients with rare ALK gene fusions: A case series and literature review.
Li M; An Z; Tang Q; Ma Y; Yan J; Chen S; Wang Y
J Cell Mol Med; 2021 Oct; 25(19):9476-9481. PubMed ID: 34541785
[TBL] [Abstract][Full Text] [Related]
7. Assessment of Alectinib vs Ceritinib in ALK-Positive Non-Small Cell Lung Cancer in Phase 2 Trials and in Real-world Data.
Wilkinson S; Gupta A; Scheuer N; Mackay E; Arora P; Thorlund K; Wasiak R; Ray J; Ramagopalan S; Subbiah V
JAMA Netw Open; 2021 Oct; 4(10):e2126306. PubMed ID: 34618040
[TBL] [Abstract][Full Text] [Related]
8. Alectinib: A Review in Advanced, ALK-Positive NSCLC.
Paik J; Dhillon S
Drugs; 2018 Aug; 78(12):1247-1257. PubMed ID: 30030733
[TBL] [Abstract][Full Text] [Related]
9. Transformation of ALK rearrangement-positive adenocarcinoma to small-cell lung cancer in association with acquired resistance to alectinib.
Takegawa N; Hayashi H; Iizuka N; Takahama T; Ueda H; Tanaka K; Takeda M; Nakagawa K
Ann Oncol; 2016 May; 27(5):953-5. PubMed ID: 26811347
[No Abstract] [Full Text] [Related]
10. Alectinib treatment response in lung adenocarcinoma patient with novel EML4-ALK variant.
Song P; Zhang J; Shang C; Zhang L
Thorac Cancer; 2018 Oct; 9(10):1327-1332. PubMed ID: 30133144
[TBL] [Abstract][Full Text] [Related]
11. Two novel ALK mutations mediate acquired resistance to the next-generation ALK inhibitor alectinib.
Katayama R; Friboulet L; Koike S; Lockerman EL; Khan TM; Gainor JF; Iafrate AJ; Takeuchi K; Taiji M; Okuno Y; Fujita N; Engelman JA; Shaw AT
Clin Cancer Res; 2014 Nov; 20(22):5686-96. PubMed ID: 25228534
[TBL] [Abstract][Full Text] [Related]
12. EML4-ALK, a potential therapeutic target that responds to alectinib in ovarian cancer.
Hui B; Zhang J; Shi X; Xing F; Shao YW; Wang Y; Zhang X; Wang S
Jpn J Clin Oncol; 2020 Dec; 50(12):1470-1474. PubMed ID: 32845005
[TBL] [Abstract][Full Text] [Related]
13. Sensitivity of eight types of ALK fusion variant to alectinib in ALK-transformed cells.
Furugaki K; Harada N; Yoshimura Y
Anticancer Drugs; 2022 Feb; 33(2):124-131. PubMed ID: 34520436
[TBL] [Abstract][Full Text] [Related]
14. Crizotinib for recurring non-small-cell lung cancer with EML4-ALK fusion genes previously treated with alectinib: A phase II trial.
Harada D; Isozaki H; Kozuki T; Yokoyama T; Yoshioka H; Bessho A; Hosokawa S; Takata I; Takigawa N; Hotta K; Kiura K;
Thorac Cancer; 2021 Mar; 12(5):643-649. PubMed ID: 33470536
[TBL] [Abstract][Full Text] [Related]
15. Activity of Brigatinib in the Setting of Alectinib Resistance Mediated by ALK I1171S in ALK-Rearranged Lung Cancer.
Sehgal K; Peters MLB; VanderLaan PA; Rangachari D; Kobayashi SS; Costa DB
J Thorac Oncol; 2019 Jan; 14(1):e1-e3. PubMed ID: 29981924
[No Abstract] [Full Text] [Related]
16. Early Alectinib Resistance From MET Amplification in ALK-Rearranged NSCLC: Response to Crizotinib with Re-Response to Alectinib and Crizotinib.
Ji J; Mitra A; Camidge DR; Riess JW
Clin Lung Cancer; 2021 Nov; 22(6):e851-e855. PubMed ID: 34059475
[No Abstract] [Full Text] [Related]
17. Alectinib-responsive infantile anaplastic ganglioglioma with a novel VCL-ALK gene fusion.
Yamamoto S; Koga Y; Ono H; Goto H; Hata N; Yamamoto H; Suzuki SO; Sakai Y; Iwaki T; Ohga S
Pediatr Blood Cancer; 2021 Sep; 68(9):e29122. PubMed ID: 34019333
[No Abstract] [Full Text] [Related]
18. Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study.
Goto Y; Yamamoto N; Masters ET; Kikkawa H; Mardekian J; Wiltshire R; Togo K; Ohe Y
Adv Ther; 2020 Jul; 37(7):3311-3323. PubMed ID: 32472430
[TBL] [Abstract][Full Text] [Related]
19. Dramatic response to alectinib in a patient with ALK-rearranged squamous cell lung cancer.
Shiihara J; Ohyanagi F; Amari H; Toda M; Tahara H; Yuzawa M; Maeda Y; Nomura M; Mizushina Y; Nagai Y; Ohta H; Yamaguchi Y
Thorac Cancer; 2021 Sep; 12(17):2420-2423. PubMed ID: 34324792
[TBL] [Abstract][Full Text] [Related]
20. Intracranial and Systemic Response to Alectinib in a Patient with RET-KIF5B Oncogenic Fusion.
Velcheti V; Ahluwalia M
J Thorac Oncol; 2017 Jul; 12(7):e98-e99. PubMed ID: 28629549
[No Abstract] [Full Text] [Related]
[Next] [New Search]